The current findings, however, highlight its potential dual applicability, reinforcing the value of drug repurposing strategies in targeting converging molecular mechanisms, particularly involving PRKAG3 dysregulation in sarcoidosis LC overlapping conditions. The gene discussed is PRKAG3; the disease is sarcoidosis.